Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Syn2bio's selling, general, & admin. expense for the
six
months ended in Sep. 2025 was zł0.00 Mil.
Syn2bio does not have enough years/quarters to calculate its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2025.
Syn2bio (WAR:S2B) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Syn2bio Selling, General, & Admin. Expense Related Terms
Syn2bio Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Syn2bio's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syn2bio Selling, General, & Admin. Expense Chart
Syn2bio Annual Data
Trend
Sep23
Sep24
Sep25
Selling, General, & Admin. Expense
0.00
0.00
0.00
Syn2bio Semi-Annual Data
Sep23
Sep24
Sep25
Selling, General, & Admin. Expense
0.00
0.00
0.00
WAR:S2B vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Syn2bio's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syn2bio Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syn2bio's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Syn2bio's Selling, General, & Admin. Expense falls into.
Syn2bio Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
What does a Selling, General, & Admin. Expense of zł Mil mean?
Syn2bio (WAR:S2B) has a Selling, General, & Admin. Expense of zł Mil as of Sep. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Syn2bio and its competitors.
Is Syn2bio's Selling, General, & Admin. Expense too high?
Syn2bio's current Selling, General, & Admin. Expense is zł Mil. Overall, Syn2bio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Selling, General, & Admin. Expense compare to VRTX and REGN?
Syn2bio's Selling, General, & Admin. Expense of zł Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Syn2bio and its competitors. Syn2bio's current Selling, General, & Admin. Expense is zł Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Selling, General, & Admin. Expense of zł Mil. The current Selling, General, & Admin. Expense is zł Mil. Syn2bio's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Selling, General, & Admin. Expense is zł Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
9GF Score
Get the complete analysis for WAR:S2B
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:S2B has been successfully added to your 
